As Congress returns from its August recess this week, groups representing the biotechnology and drug industries are making last-ditch efforts to influence the outcomes of bills that affect product safety, patent laws and generic competition. (BioWorld Today)
As Congress returns from its August recess this week, groups representing the biotechnology and drug industries are making last-ditch efforts to influence the outcomes of bills that affect product safety, patent laws and generic competition. (BioWorld Today)
The FDA gave its nod of approval to Omrix Biopharmaceutical Inc.'s Evithrom, the first standalone human thrombin product approved since 1954 and the only such product with U.S. licensing. (BioWorld Today)
The FDA gave its nod of approval to Omrix Biopharmaceutical Inc.'s Evithrom, the first standalone human thrombin product approved since 1954 and the only such product with U.S. licensing. (BioWorld Today)
